Microvascular Stenosis in Critical Limb Ischemia: Role of Partial Endothelial to Mesenchymal Transition by Chevalier, Jacqueline M
Western University
Scholarship@Western
Electronic Thesis and Dissertation Repository
August 2019
Microvascular Stenosis in Critical Limb Ischemia:
Role of Partial Endothelial to Mesenchymal
Transition
Jacqueline M. Chevalier
The University of Western Ontario
Supervisor
Pickering, J. G.
The University of Western Ontario
Graduate Program in Medical Biophysics
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science
© Jacqueline M. Chevalier 2019
Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Biochemistry Commons, Biophysics Commons, Cardiovascular Diseases Commons,
Medical Biophysics Commons, Molecular Biology Commons, and the Other Biochemistry,
Biophysics, and Structural Biology Commons
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Electronic Thesis
and Dissertation Repository by an authorized administrator of Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.
Recommended Citation
Chevalier, Jacqueline M., "Microvascular Stenosis in Critical Limb Ischemia: Role of Partial Endothelial to Mesenchymal Transition"





BACKGROUND: Peripheral artery disease (PAD) is a major cause of morbidity and 
mortality that arises from atherosclerotic vascular disease. Severe PAD, or critical limb 
ischemia (CLI) in the extremities can lead to recurrent pain, non-healing ulcers, gangrene, 
and often requires amputation. Unfortunately, surgical and percutaneous 
revascularization strategies for CLI are often unsuccessful. A major reason for disease 
recurrence and treatment failure is likely co-existing abnormalities in the distal 
microvasculature. However, these small vessels are not seen clinically and there is little 
known about their structure and function in patients with PAD. The status of the 
microcirculation in ischemic muscle could be critical to informing strategies for modulating 
and potentially normalizing the distal vasculature in PAD.  
The purpose of this study was to delineate abnormalities in the 
microvascular wall in the ischemic skeletal muscle of patients with CLI.   
 
METHODS: To elucidate the microvascular landscape in CLI, we studied human tibialis 
anterior (TA, n=14) and gastrocnemius (n=10) muscles harvested from below-knee or 
above knew leg amputations of 10 individuals with CLI. Control muscles, from individuals 
without PAD, were obtained from TA (n=2) and vastus lateralis (n=4) samples. Formalin 
fixed, paraffin-embedded muscle sections were stained with hematoxylin and eosin, 
Mason’s trichrome and immunostained for endothelial cell maker, CD31, the 
mesenchymal cell markers, N-Cadherin, smooth muscle-a-actin, S100A4, and Snail, and 
the signaling molecules pSMAD2/3, TGFß1, and Endgolin. 
  
RESULTS: CLI but not Non-PAD samples had myofiber damage features. Capillary 
density, quantified from CD31-stained sections, was 1.8-fold higher in CLI skeletal muscle 
(*p=0.009). Furthermore, the density of small arterioles (8 - 40 µm diameter) was also 
significantly increased in CLI samples (*p=0.0002). Surprisingly, the arterioles in subjects 
with CLI, particularly those 8 - 20 µm in diameter, were found to be stenotic, with at least 
a 40% reduction in lumen area. Moreover, the area of the endothelium was 1.2-fold 
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greater (*p<0.0001) in arterioles of CLI patients. The endothelial cells themselves 
underwent a reorientation and were rounded, causing them to obstruct the lumen 
(*p<0.0001). Notably, 9% of the small arterioles in CLI patients were completely occluded, 
while an additional 33% were stenotic.  
These aberrant endothelial cells showed a striking shift in N-cadherin localization, 
from diffuse staining to junctional and apical enrichment, in addition to overall 
upregulation within the small arterioles of CLI patients (*p=0.0007). Furthermore, the 
obstructive endothelial cells expressed CD31 along with mesenchymal cell markers 
S100A4 and Snail, indicating partial endothelial to mesenchymal transition (EndMT). To 
determine the mechanism of activation for the partial EndMT. Immunostaining for 
activated, pSMAD2/3 revealed a 1.4-fold higher signal in endothelial cells of CLI arterioles 
(*p=0.0078). As well, the mural cells of CLI arterioles had a 63-fold higher expression of 
TGFß1 than control arterioles, together implicating TGFß signaling in driving the EndMT 
process in CLI arterioles.  
 
CONCLUSIONS: Skeletal muscles of patients with critical PAD demonstrated endothelial 
cell-based arteriolar stenosis, a previously unidentified phenomenon.  The bulky and 
reoriented endothelial cells expressed mesenchymal markers and had evidence for 
augmented TGFß signaling.  The findings suggest a newly recognized structural basis for 








Keywords: endothelial to mesenchymal transition, arterioles, microvasculature, critical 
limb ischemia, skeletal muscle, endothelial cell, N-cadherin, TGFß 
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SUMMARY FOR LAY AUDIENCE  
The muscles that exist in our legs require a tremendous amount of blood to keep 
healthy.  In some individuals, the blood supply to the legs is impaired because of plaque 
build-up in the arteries that deliver the blood to the legs.  When severe, this can result in 
severe leg pain, skin ulcers that don’t heal, and ultimately, it may require the leg to be 
amputated.  Diabetics are especially prone to this serious problem. 
The main treatment for severe blood vessel disease in the legs is surgical bypass 
or stenting.  However, these procedures are not effective for many individuals and an 
amputation is still necessary.  This is a major and world-wide problem. 
One reason surgery is ineffective for so many individuals is that not only is there 
plaque build-up in the leg arteries, but there is also narrowing of the tiny blood vessels – 
called arterioles – that dive into the muscles themselves.  However, because these 
vessels are so small, they are exceedingly difficult to study.   
In this thesis, I have established that in legs that have sufficiently poor blood flow 
that an amputation is necessary, there is a serious problem with the small arterioles.  I 
examined tissue from these legs using highly sophisticated microscopy techniques.  I 
discovered that the inner lining of arterioles is no longer thin and smooth. Instead, the 
cells that make up the inner lining, called endothelial cells, become so bulky that they clog 
the small channels, preventing the blood from flowing.  I also discovered that these 
endothelial cells actually convert into a different type of cell that has a tendency to stick 
to its nearby neighbours, a bad situation for blood vessels. 
These discoveries could explain why bypass procedures fail in many people, 
because the small clogged arterioles cannot be bypassed.  The findings could also open 
possibilities for new strategies to improve the blood flow in individuals with narrowing of 
the leg arteries. 
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1 CHAPTER 1:  
GENERAL INTRODUCTION  
 
Peripheral artery disease (PAD) is a major cause of morbidity and mortality in 
North America.1 It is a disease that arises from atherosclerosis in arteries other than those 
that supply the heart and brain. Severe PAD in the extremities can lead to recurrent pain, 
non-healing ulcers, gangrene, and often requires amputation.1 Unfortunately, surgical and 
percutaneous revascularization strategies for PAD are often unsuccessful. A major 
reason for disease recurrence and treatment failure is likely co-existing abnormalities in 
the distal microvasculature.2 However, these small, distal vessels are not assessed 
clinically and there is little known about their structure and function in patients with PAD.  
Recently, our research group has discovered several unexpected microstructural 
and network abnormalities that develop in the hindlimb microcirculation of mice following 
severe ischemic injury.3 However, the nature of and extent to which skeletal muscle 
microvascular restructuring proceeds in humans with chronic severe PAD is unknown.  
This could be critical to informing strategies for modulating and potentially normalizing the 
distal vasculature in PAD. Accordingly, the overarching purpose of my thesis was to 
elucidate microvascular abnormalities in skeletal muscle of patients suffering from severe 
peripheral artery disease.  
 
My specific objective was: 
To delineate abnormalities in the wall of microvessels in critically ischemic skeletal 
muscle, with a focus on endothelial cell phenotypes.  
 
1.1 Peripheral Artery Disease 
Peripheral artery disease (PAD) is caused by accumulation of atherosclerotic plaque 
in the arteries that supply organs other than the heart and brain, with the lower legs being 
the most commonly affected (Figure 1.1).1 PAD is often diagnosed by a reduction of the 
















Figure 1.1 Schematic Representation of Peripheral Artery Disease  
 
Peripheral artery disease is a consequence of atherosclerotic plaque build-up in large 
and medium size arteries which limits blood supply primarily to the lower limbs. Clinically, 
the small vessels cannot be visualized, limiting treatment to the larger vessels.   
 






artery to the highest blood pressure in the brachial artery.1 Cardiovascular risk factors for 
PAD include smoking, diabetes, hypertension, and dyslipidemia; but in particular smoking 
and diabetes are associated with worse outcomes, independent of other risk factors.4–6  
PAD can affect the leg both at rest and during exercise, and its progression leads to one 
of two clinical manifestations: intermittent claudication and critical limb ischemia (CLI).1,4 
Intermittent claudication is characterized as calf or buttock pain during exercise and is 
relieved by rest. By contrast, CLI results in extreme pain even while at rest. Consistent 
with this continuous ischemia, CLI is often associated with ulcers or gangrene. In the 
absence of successful revascularization, 20% to 40% of patients will require amputation, 
resulting in poor quality of life, contributing to long-term disability and severe functional 
impairment, which leads to significant costs in health care.4,5,7,8  
The goals of treatment for patients with intermittent claudication are to relieve the 
symptoms, improve walking capacity, and improve quality of life. In cases of CLI, along 
with these goals, there is the additional intent to relieve ischemic pain at rest, heal 
ulceration, and prevent limb loss.9 In the early stages of PAD, medical professionals 
encourage risk factor reduction and lifestyle modification, including exercise rehabilitation 
and ceasing smoking. The use of antiplatelet drugs and Angiotensin-Converting-Enzyme 
(ACE) inhibitors to reduce cardiovascular risk are also commonly used. Additionally, 
recent trials of direct oral anticoagulants have shown promise.10  
CLI is typically an end-stage presentation of PAD and is currently treated via 
surgical and endovascular revascularization procedures, with surgical bypass remaining 
the gold standard for revascularization for these patients. However, many of the patients 
suffering from CLI are poor candidates for revascularization procedures, and for the few 
that are eligible, there is a high rate of reoccurrence.4,7 For those that are fortunate 
enough to undergo a revascularization procedure, whether it is surgical bypass or 
endovascular therapies, about 25 – 66 % will fail to survive with an intact limb at 1 year.11 
A major reason for disease recurrence and treatment failure is believed to be co-existing 
abnormalities in the distal microvasculature.2 However, these small vessels are not 
visualized with the standard clinical angiography techniques. In fact, little is known about 
their structure and function in patients with PAD. 
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1.2 Skeletal Muscle  
The skeletal muscle of the leg is the primary organ affected by CLI.1  The skeletal 
muscle is a metabolically active tissue which allows it to generate longitudinal contraction. 
As such, it requires a large amount of blood flow during both rest and exercise to support 
its metabolic activity, making it very vulnerable in patients with PAD.  
Skeletal muscles consists of bundles of parallel and dense muscle fiber, which are 
comprised of multinucleated cells derived from myoblasts.12,13 The myofibers are closely 
packed together and surrounded by the endomysium. Groups of myofibers will be 
wrapped into bundles called fascicles surrounded by perimysium, which will then be 
bundled to create a whole muscle. This highly organized, highly cellular tissue generates 
longitudinal contraction because of the strict cellular orientation.12,13  
In normal muscle repair following acute injury, damaged or dead myofibers will be 
digested and removed by macrophages.12–14 Satellite cells, a specialized stem cell sub-
population, initiate regeneration in response to specific local factors. They begin to 
proliferate and will differentiate into myoblasts which then fuse to form the multinucleated 
and elongated myotubes which combine to form muscle fibers. The basal lamina can 
serve as a scaffold for the reconstruction of the regenerating muscle fibers. By contrast, 
if the injured area has had disruption of the basal lamina by fibrosis, then the complete 
regeneration of muscle fibers may be inhibited.12–14 Myofiber regeneration plays an 
important role in the skeletal muscle recovery from ischemic injury (See Section 1.4.1 
Muscle Histopathology in CLI).  
 
1.3 The Skeletal Muscle Circulation   
The microcirculation contains the smallest blood vessels within the cardiovascular 
system, ranging from 5 µm to ~150-200 µm in diameter.15 The microvasculature is 
responsible for delivering oxygen and nutrients to all cells within the body, including the 
skeletal muscle.16 It is a tightly regulated system which precisely controls the amount of 
oxygen-rich blood sent to areas within an organ in order to meet the metabolic demands 
of the tissue with the goal of maintaining homeostasis.16 Key aspects of the 
 6 
microvasculature which allow it to function effectively include: the architecture, the 
hierarchy, and the cellular structure of the microvessels.  
 
1.3.1 Microcirculation Architecture and Hierarchy  
The basic unit of blood flow control is the microvascular unit (Figure 1.2), which is 
comprised of an arteriole, terminal arteriole (pre-capillary arteriole), capillary network, 
post-capillary venule, and venule.3 The arterioles and terminal arterioles regulate the flow 
of oxygen-rich blood into downstream capillaries by dilation and constriction in response 
to the metabolic demand of the tissue.17 The capillaries supply oxygen by passive 
diffusion to the surrounding tissue.18 Following oxygen exchange to the tissue, the 
capillary network will drain into post-capillary venules, which will feed into the venous 
return system.  
In the skeletal muscle, arteries symmetrically bifurcate and branch into arterioles 
and terminal arterioles which run in an orthogonal orientation to the muscle fibers. The 
terminal arterioles then branch into capillary networks which run parallel to and between 
the muscle fiber. Skeletal muscle capillaries are 4-8 µm in diameter19 and approximately 
0.5-1 mm in length.20 The red blood cells (RBC) are approximately 4-8 µm in diameter 
and therefore travel in single file in a normal capillary. Given that RBCs transiting in 
capillaries provide oxygen to the surrounding tissue by passive diffusion, there is a limited 
volume of tissue which each capillary can feed. It is therefore necessary for anastomoses 
in capillary networks to sufficiently supply oxygen to the tissue. Additionally, the capillaries 
are embedded within sarcolemmal depressions in order to maximize the contact surface 
area between myocytes and the capillaries.21 The mitochondria line these grooves in 
order to minimize the diffusion distance for the oxygen to reach them.21 The post-capillary 
venules are located between two terminal arterioles and collect the deoxygenated blood 
from the capillary beds. Ultimately, the blood drains into the larger veins which are found 

















Figure 1.2 The Microvascular Unit in Skeletal Muscle  
 
The basic unit of tissue blood flow is the microvascular unit. In the skeletal muscle, 
arteries symmetrically bifurcate and branch into arterioles and terminal arterioles. The 
latter ran orthogonal to the muscle fibers. The terminal arterioles branch into capillary 
beds and capillaries which run parallel and between the muscle fibers. Capillaries are 
embedded within grooves in the muscle fibers, and the myocyte mitochondria are closely 
opposed to these grooves in order to maximize the contact surface area between 






1.3.2 Microcirculation Cellular Structure  
Each order of microvessels in the microcirculation has a specific and critical cellular 
structure that allow them to achieve the unique roles within the microvascular unit (Figure 
1.3). Below are the key cell types that make up this structure.  
 
1.3.2.1 Endothelial Cells  
All the vessels of the circulatory system are channels lined with a single layer of 
endothelial cells (EC). The endothelium acts as a semi-permeable barrier which controls 
the transfer of small and large molecules from the vessels to surrounding tissues.22 
Healthy endothelial cells are vital for the maintenance of vascular homeostasis. 
Endothelial cells are responsible for modulating vascular tone, controlling vessel 
permeability, and controlling immune responses by regulating the adherence of platelets, 
and leukocytes to the inner vessel wall. The properties of healthy endothelial cells 
contribute to the maintenance of normal blood fluidity by their anticoagulant and 
antiplatelet effects .23  
There are numerous examples of how the microenvironment can regulate the 
endothelial cell phenotype. Recent studies have shown that endothelial cells may be 
derived from different local progenitor cells depending on the organ or tissues in which 
they are found. Endothelial cell differences have been found between arteries and veins, 
large and small vessels, and different microvascular beds in various organs and tissues. 
Some organ-specific endothelial cell properties include vessel barrier functions, 
angiogenic potential, and metabolic functions.24 To add to the complexity of organ and 
vessel-specific endothelial cells, there are also multiple subpopulations of endothelial 
cells being found, such as tip and stalk cells.25 
A distinct but related process is endothelial cell plasticity and transdifferentiation 
(see section 1.5.2 Endothelial to Mesenchymal Transition). Endothelial cells have the 
innate ability to sense and respond to environmental factors by changing their phenotype. 
This phenotypic plasticity reflects endothelial cell exposure to growth factors, cytokines, 


















Figure 1.3 The Cellular Structure of the Microvasculature  
 
All the arterioles and capillaries that are part of the microcirculation are made up of 
endothelial cell-lined channels which are surrounded by mural cells. The pericyte is the 
predominant mural cell for capillaries. In contrast, the arterioles will be circumferentially 














the endothelial cell quiescent state is an active process. Key proteins such as vascular 
endothelial growth factor receptor 2 (VEGFR2) and fibroblast growth factor receptor 1 
(FGFR1) play important roles in maintaining endothelial cell homeostasis.26  
 
1.3.2.2 Mural Cells  
In addition to the endothelial layer, all orders of blood vessels have various supporting 
or mural cells, which is a key point of distinction between different orders of microvessels. 
Pericytes are a type of mural cell that surround the capillaries, which are the smallest of 
the microvessels. In contrast to the capillaries, the contractile vascular smooth muscle 
cells (SMC) contribute to the vascular wall of larger vessels, arterioles and venules.27,28 
SMCs and pericytes can share many cellular markers and in some cases are best 
distinguished by their morphology and location within the vasculature.29  
The current accepted definition of a mature pericyte is a cell that is embedded within 
the endothelial basement membrane.29 Pericytes can be mistaken for other peri-vascular 
cells such as SMCs, fibroblasts, macrophages and epithelial cells, which are not located 
within the basement membrane of the endothelial cells.  A key morphological marker for 
pericytes is the presence of primary cytoplasmic processes extending along the surface 
of the endothelial tubes with secondary processes that attach to the endothelium. 30  
Pericytes often span across more than one endothelial cell, yet, in the skeletal muscle, 
many endothelial cells are without pericyte contact.30   
By contrast, SMCs circumferentially wrap the larger microvessels and are contractile, 
with expression of smooth muscle-α-actin and other contractile proteins to allow 
constriction and relaxation.3 A single SMC layer surrounds the small arterioles and 
terminal arterioles. Arteriole SMCs have a long, spindle-shaped appearance with few 
cytoplasmic processes, whereas around the pre-capillary (terminal) arterioles, the SMC 
bodies are distinctly bulky and extend several processes encircling the endothelium.30 By 
contrast, on the other end of the capillary bed, SMCs on the post-capillary venules have 
a compressed cell body with many slender, branching processes. SMCs on venules have 
large, stellate shaped bodies with many branching processes which do not wrap 
circumferentially.30  
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The cellular architecture of the varying vessels reflects their specific roles within the 
microcirculation. Whereas the arterioles require a circumferential wrapping to allow for 
effective blood flow control by uniform constriction and relaxation of the whole vessel, the 
capillaries require only supporting mural cells with little contractile properties. The venules 
require the support and stability of the SMC without the need for circumferential wrapping 
required for contractile function in arterioles.  
 
1.3.3 Functional Interplay Between Endothelial Cells and Mural Cells 
The interactions between endothelial cells and mural cells play a key role in biological 
processes such as angiogenesis and arteriogenesis. While evaluating the endothelial-
pericyte interactions, studies highlight that impairment of one of the vessel wall cell types 
will impact the other.31 In addition to impacting one another in pathological processes, the 
relationship between endothelial cells and mural cells plays a key role in vascular 
development and homeostasis.   
  
1.3.3.1 Angiogenesis  
Angiogenesis is the process by which new blood vessels develop from a pre-
existing vasculature.32 Over time, this network remodels into a differentiated network of 
arteries, capillaries, and veins. Angiogenesis most often occurs by a process termed 
sprouting angiogenesis, the goal of which is to generate new microvessels and capillaries 
in tissue regions with insufficient blood flow.32 
Sprouting angiogenesis occurs by activation of endothelial cells from a basal 
quiescent state with the breakdown of endothelial cell junctions and increase of vessel 
permeability. These changes allow the migration of an endothelial cell tip cell toward a 
gradient of angiogenic factors that are produced in hypoxic tissues. The tip cells signal to 
their neighboring stalk cells to proliferate and extend the length of the sprout while 
suppressing migratory behaviour, as well as generating basement membrane 
components and establishing junctions with neighboring endothelial cells. Following 
sprout formation, the lumenization of the vessel will ensue.33,34 
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Although the endothelium has received the majority of study in regard to 
angiogenesis, mural cells are recognized to be necessary to stabilize nascent vessels by 
inhibiting endothelial proliferation and migration, and by stimulating production of 
extracellular matrix.32 During angiogenesis, the endothelial cells will release platelet-
derived growth factor-B (PDGF-B) for paracrine signaling through PDGF receptor-b 
(PDGFRb) on pericytes stimulating their proliferation and recruitment along the sprouts. 
Pericyte recruitment at this stage plays a crucial role in vascular stability, without which 
there are leaky vessels and loss of capillary diameter control.35 Angiopoietin-Tie ligand-
receptors are similarly important for endothelial-mural cell association, but they work 
through an inversed loop, from mural cells to the endothelium. Ang-1 is predominantly 
expressed by mural and other perivascular cells, while Tie2 is expressed in the 
endothelium. Studies have suggested that Tie2 and Ang-1 play important roles in 
angiogenic sprouting and vascular remodeling, as well as association between 
endothelial and surrounding mesenchymal cells and matrix.36 Although this is an overview 
of the signaling involved in angiogenesis and mural cell recruitment, the paracrine 
signaling pathways described highlight the critical role of endothelial-mural cell interplay 
in angiogenesis and vascular stability.  
Endothelial cells and mural cells can also respond to each other as secondary 
consequences of upstream signaling, in addition to paracrine signaling. For example, 
sphingosine-1-phosphate (S1P) is necessary for vascular maturation and is in high 
concentration within the plasma and serum.37 S1P activates a family of G protein-coupled 
receptors (S1P1 to 5) in the endothelium. S1P1 plays a role in vascular endothelial cadherin 
(VE-cadherin) assembly into adherens junctions and is critical for endothelial cell 
morphogenesis into capillary-like structures in vitro. Notably, N-cadherin, a cell adhesion 
molecule which connects endothelial cells to mural cells, has been shown to be activated 
and subsequently relocated to basal plasma membrane domains via S1P/S1P1 signaling. 
S1P is critical for proper trafficking of N-cadherin to cell adhesions between endothelial 
and mural cells. It has been suggested that clustering and activation of local N-cadherin 
on the basal endothelial cell surface by S1P1 may induce clustering of N-cadherin on the 
neighboring mural cells.36–38 
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Similarly, TGFb signaling plays a role in both endothelial cells and mural cells. It 
has been shown that if TGFb signaling in endothelial cells is impaired, the adjacent 
mesenchymal cells showed impaired TGFb/ALK5 signaling, inhibiting their differentiation 
into vascular SMCs and their association with the endothelium.31 Specifically, TGFb 
signaling in endothelial cells promotes TGFb expression, synthesis, and release by these 
cells, which induces differentiation of vascular SMC from surrounding mesenchymal cells. 
The process also reinforces TGFb expression in the endothelial cells in an autoregulatory 
loop.31 In contrast, the role of mural cell-derived TGFb during angiogenic remodelling 
remains largely uncharacterized.  
 
1.3.3.2 Arteriogenesis and Collateralization 
While angiogenesis is necessary for delivery of blood and oxygen to ischemic and 
regenerating tissues, arteriogenesis plays a major role in increasing bulk blood flow and 
volume to the microvessels. Arteriogenesis is a process by which pre-existing collateral 
arteries will enlarge into larger diameter conductance vessels.32 This remodeling 
response is primarily driven by increased fluid shear stress, typically caused by the 
occlusion of major arteries and diversion of flow into collateral vessels, for example in 
PAD. It is characterized by the proliferation of endothelial cells and SMCs and a process 
of luminal expansion and vessel wall thickening to support an increased blood flow and 
shear stress.33,34  
 
1.4 Critical Limb Ischemia  
Despite the decrease in arterial flow caused by atherosclerotic build-up in the feeding 
arteries, the basis for the impaired functional capacity of patients with PAD remains 
controversial. In particular, altered hemodynamics does not entirely explain the degree of 
functional limitations in patients with PAD.39,40 Furthermore, studies have not evaluated 





1.4.1 Muscle Histopathology in CLI 
Muscle regeneration following injury is crucial for organism survival. This process 
occurs by the successful completion of a series of events that, if disrupted, can result in 
persistent degeneration of myofibers, inflammation, and fibrosis.41 Muscle regeneration 
occurs by the following process:  
1) Injured skeletal muscle, injured blood vessels, and infiltrating inflammatory cells 
will release cytokines and growth factors, which stimulate the migration of the 
inflammatory cells to the site of injury.  
2) Invading inflammatory cells are responsible for phagocytosing cellular debris from 
the injury.  
3) Satellite cells then begin their role in the formation of new muscle fibers by their 
activation, followed by proliferation, and finally differentiation.  
4) The differentiated myoblasts fuse to each other to form de novo fibers, or to the 
damaged myofibers to replace lost muscle. Often, the satellite cells will use the 
basement membranes of pre-existing necrotic fibers to ensure the myofiber 
maintains a similar position.   
5) The migration and proliferation of fibroblasts will help produce new temporary 
extracellular matrix components which assist in stabilizing the tissue, and act as 
scaffolds for the new fibers.12–14,42  
This innate mechanism for muscle regeneration can be altered by chronic ischemia. 
For example, chronic ischemia can induce the proliferation of satellite cells but inhibit their 
differentiation, resulting in limited repair of the skeletal muscle.14,43 Consistent with the 
limited repair of muscle in PAD, several laboratories have demonstrated that there is 
additional myopathy present in the leg of patients with PAD. These abnormalities include 
myofiber degeneration with alterations of the size and shape of myofibers, internal nuclei, 
vacuolization, shift of myofiber type toward type I fibers, myofiber necrosis (Zenker’s 





1.4.2 Microvascular Pathology in PAD 
Little is known about the state of the microvasculature in patients with CLI. 
However, there is evidence that the condition of the microcirculation could determine the 
outcome of revascularization procedures.50 Recently, studies have begun to characterize 
the microvasculature of patients with PAD.  
Studies have evaluated the capillary density in patients with PAD to determine the 
extent of angiogenesis in the ischemic limb. Some studies have indicated that humans 
have angiogenic capabilities, showing an increase in the capillary and microvascular 
density in patients with PAD. 51–55 Others have found no significant change, or decrease 
in capillary density in patients with PAD. 40,56–59  
Additionally, it has been shown that the capillaries in patients with PAD have a 
thickened basement membrane. This thickened layer of the basement membrane 
contains more SM-a-actin positive cells, although it is uncertain whether these cells are 
pericytes, fibroblasts, or SMC. It was further suggested that the capillaries in the skeletal 
muscle of patients with PAD might be converted to arterioles, as has been shown in the 
rats in response to increased blood flow, stretch and muscle activity.60  
At the level of the small arteries (<500µm) in the subcutaneous fat and skeletal 
muscle vascular beds of patients with CLI, it was shown that there is a reduction in the 
media to lumen ratio due to SMC remodelling of the vessels.2,61  This remodelling inhibited 
the ability of the atrophied vessels in the ischemic vascular bed to vasodilate. It was also 
shown that the arterioles in the subcutaneous tissue showed an opposite effect with an 
impaired vasoconstriction response. This contrast could lead to blood being diverged from 
the muscle to the skin and could be the basis of a redistribution phenomenon.61  
Finally, studies have evaluated the endothelium’s impaired nitric oxide signaling, 
decreased nitric oxide dependent reactivity, excessive inflammation, and a delayed or 
diminished response to angiogenic factors in patients with PAD.50,60–67 However, it 
remains elusive how the phenotype of microvascular endothelial cells contributes to the 




1.4.3 Ischemic Mouse Model  
Inducing ischemia in the hindlimb of mice constitutes a useful model to study PAD. 
Femoral artery ligation or excision provides a simple model with ease of access and a 
low mortality rate.68 A recent study by Arpino et al. in the ischemic mouse model has 
shown that following severe ischemic insult the regenerated microvasculature contains 
abnormalities and flaws.3   
Compared to the mouse model, human disease is more complex with many 
confounding factors that could impact the microvasculature. These factors include: 
metabolic stress from aging, disease progression over decades rather than an acute 
injury, and poorer native regenerative ability of the microvasculature in humans compared 
to that found in the mouse. It is acknowledged that in both small and large animal models 
of PAD, the rapid collateralization that is not seen in patients diminishes the time of 
ischemia. Also many models rely on induced injury which can contaminate the tissue with 
physical injury.69  It is therefore crucial to evaluate the structure and functional attributes 
of the microvasculature of human skeletal muscle in CLI. 
 
1.5 Cellular Plasticity 
The vascular wall is known to play a central role in maintaining homeostasis of the 
cardiovascular system. Endothelial cells and mural cells show a wide range of plasticity 
and differentiation potential. These processes present new opportunities to understand 
organ maintenance, and new methods to moderate disease progression, improve 
vascular repair, and promote regeneration.  
 
1.5.1 Mural Cell Plasticity: Pericytes and vascular smooth muscle cells 
Research in pericyte plasticity and identification is a quickly evolving field. The 
accepted definition of a mature pericyte is a cell embedded within the vascular basement 
membrane.30 N-cadherin is distributed in a potted fashion along the endothelium-pericyte 
interface, a pattern that is disrupted when pericytes are absent.29 Pericytes are found in 
capillaries, post capillary venules, and terminal arterioles. As SMCs and pericytes belong 
to the mesenchymal cell lineage, they can be difficult to distinguish. There is currently no 
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known single molecular marker that can be used to unequivocally identify pericytes and 
distinguish them from SMC or other mesenchymal cells. This creates a limitation in 
defining any microvascular periendothelial mesenchymal cell without investigating 
whether they share a basement membrane. When an ultrastructural analysis is 
impractical, pericytes are usually defined using a mixture of criteria including location, 
morphology, and gene/protein expression.29,30,70  
Pericyte morphology is described as having a cellular body that extends primary 
cytoplasmic processes along the abluminal surface of the endothelial tube 30,71. These 
processes usually span several endothelial cells in human skeletal muscle. Thin 
secondary processes extend perpendicularly from the primary processes, encircling the 
vessel. In terms of gene and protein expression, validated markers include platelet-
derived growth factor receptor-beta (PDGFRb), chondroitin sulfate proteoglycan 4 (NG2), 
alanyl aminopeptidase (CD13) and desmin.  
Mural cell plasticity is still largely unclear because we do not know the extent that 
new pericytes develop by division of pre-existing pericytes, by recruitment from pre-
existing SMCs on neighboring large vessels, or by transdifferentiation of other 
mesenchymal cells. The continuum of mural cell phenotype observed along terminal 
arterioles, capillaries, and post-capillary venules could suggest that these cells can 
differentiate into each other in conjunction with vessel growth and remodeling.30,71  
Intracellular signaling between the endothelial cells and the mural cells help to 
maintain vascular homeostasis. As noted above, pathways such as PDGF-B, TGFb and 
angiopoietin play significant roles in vascular development and stability. In particular 
TGFb upregulation has been shown to lead to the activation of receptor Alk-5 in 
mesenchymal cells which consequently phosphorylates SMAD2/3 and thereby promotes 
mitotic and migratory quiescence and differentiation into SMC. By contrast, activation of 
Alk-1 leads to phosphorylation of SMAD1/5 which promotes cell proliferation and 
migration but opposes SMC differentiation. SM-a-actin has been shown to be expressed 
by some pericytes and may have a contractile role in the retina and nervous system.72 
Additionally, SM-a-actin is upregulated in pathological processes such as tumor 
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angiogenesis, tissue fibrosis, and inflammation. TGFb, which has been involved in SMC 
maturation is a potential driver of the expression of SM-a-actin in tumour pericytes.30,31,72 
 
1.5.2 Endothelial Cell Plasticity: Endothelial to Mesenchymal Transition   
Epithelial-mesenchymal transition (EMT) is an important developmental process 
which has been extensively studied in pathologies such as tumour growth.73 Recently, 
endothelial-mesenchymal transition (EndMT), a newly recognized type of cellular 
transdifferentiation, has been demonstrated to have an important role during embryo 
development. This has been well-described in regard to valve progenitor cells and cardiac 
development.26,74 EndMT is a process by which the endothelial cells will partially lose at 
least some of their endothelial cell phenotype by delaminating and invading into 
underlying tissues. The cells will lose endothelial cell markers such as VE-cadherin, 
CD31, p100-catenin, isolectin-B4 (Figure 1.4).26,73,75 Simultaneously, the cells acquire a 
mesenchymal phenotype, characterized by a loss of cell-cell junctions, acquisition of 
invasive and migratory properties, and expression of mesenchymal cell products  such 
as fibroblast specific protein-1 (FSP-1), N-cadherin, vimentin, platelet derived growth 
factor receptor beta (PDGFRb).26,73,75 These cells can then result in different 
mesenchymal cell fates such as fibroblasts and SMC.26,74  
The EndMT process is additionally thought to be important for stabilizing the 
neovasculature during vasculogenesis and angiogenesis by giving rise to vascular 
support cells such as pericytes and/or SMC. Additionally, EndMT plays an important role 
in angiogenic sprouting regulated by VEGF.74,76 Through cell lineage tracing, it has been 
shown that endothelial cells give rise to SMCs in the medial layer of the coronary arteries, 
to stem cell antigen-1 progenitor cells in the adventitial layer, and to ventricular 
cardiomyocytes during cardiac homeostasis.77 However, EndMT has also been shown to 
be a pathological process in adult valve disease, cardiac fibrosis, cancer fibrosis, and in 
myocardial responses to ischemic injury.26,73 In these cases, EndMT results in 


















Figure 1.4 Endothelial to Mesenchymal Transition  
 
EndMT is a process by which the endothelial cells partially lose at least some of their 
endothelial cell phenotype, delaminate, and invade into underlying tissues. The process 
is marked by the gradual loss of traditional EC markers such as VE-Cadherin, CD31, 
p100-catenin, and isolectin-B4, while simultaneously gaining mesenchymal cell marker 
expression such as N-cadherin, fibroblast specific protein-1, vimentin, and smooth muscle 
a-actin.  TGFb derived from microvascular niche, including enzyme-processed 






1.5.2.1 Partial Endothelial to Mesenchymal Transition  
A newly coined term - partial EndMT - describes a partial EndMT which occurs 
when one or more of the key characteristics of a complete EndMT are not exhibited, for  
example dissolution of cell-cell contacts.76 It has been suggested that partial EndMT could 
play a role in angiogenesis, as the tip cells that lead the sprout will lose their apical-basal 
polarity, degrade the basement membrane and extracellular matrix, and are migratory. 
Throughout this process, it has been additionally shown that Snail is upregulated, a well-
known transcription factor associated with EndMT.78 Studies have also associated partial 
EndMT with atherosclerotic lesion development and pulmonary hypertension.79,80  
 
1.5.2.2 EndMT and the TGFb Pathway 
The mechanism by which EndMT induction occurs is complex, involving many 
different pathways. Studies are beginning to fill in the blanks but much is still unknown 
with regards to signaling pathways in EndMT. TGFb, Wnt, CAV1, Shh, Notch1, hypoxia 
and ET-1 have also been shown to contribute to EndMT.26,73,74,81,82 For the purposes of 
this thesis, the main pathway of interest is TGFb signaling through SMADs. 
TGFb is a multifunctional growth factor that can regulate a broad range of biological 
processes including cell proliferation, cell differentiation, cell apoptosis, and cell migration. 
The TGFb signaling is mediated by the binding of members of the TGFb family binding 
specific transmembrane receptors. They bind a complex of two type I and two type II 
serine/threonine kinase receptors. Upon ligand binding, the type II receptor will 
phosphorylate the type I receptor. This will allow the type I receptor to phosphorylate 
specific transcription factors called the receptor regulated (R)- SMADs. When activated, 
the R- SMADs form a heteromeric complex with the common mediator (Co)- SMAD 
(SMAD4). These heteromeric complexes traffic into the nucleus where they regulate the 
transcription of target genes.83 Inhibitory SMADs inhibit the activation of R- SMADs by 
competing for the type I receptor interaction. They additionally recruit phosphatases and 
ubiquitin ligases to the activated receptors complex leading to dephosphorylation or 
proteasomal degradation of the receptor complex (Figure 1.5). In addition to the type I 
and type II receptors, there are the co-receptors (also called TGFb receptor III), endoglin 
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and betaglycan. These co-receptors do not signal by themselves since they lack 
intracellular enzymatic domains. However, they increase the ligand-binding affinity for the 
TGFb receptors.84 Endoglin is highly expressed in proliferating endothelial cells. 
Following the translocation of the heteromeric complexes of SMADs into the 
nucleus, the SMAD complexes interact with transcriptional co-activators and/or co-
repressors to activate or repress transcription of TGFb target genes which can encode 
EndMT. The SMAD complexes not only activate expression of EndMT genes but also 
increase the activity of EndMT transcription factors. For example, SNAI1’s transcription 
is SMAD3-dependent, whereas SNAI2 (SLUG) is induced indirectly by the SMAD3-
induced expression of myocardin-related transcription factor (MRTF). SMADs directly 
activate the expression of some mesenchymal genes, for example, those encoding 
fibronectin, vimentin, and Pro-a(I)-collagen. SMAD3-SMAD4 also cooperate with Snail to 
repress E-cadherin (VE-cadherin, CD31 in EndMT).85  
 
1.6 Aims of the Thesis  
This literature review highlights the important but limited understanding of how the 
phenotype of cells in the microvascular wall contribute to muscle ischemia and damage 
in the context of CLI.  
To address this research gap, the goal of my thesis was to delineate abnormalities 
in the arteriole wall in the skeletal muscle of patients with CLI.  
 
The purpose of this study was to delineate abnormalities in the 
microvascular wall in critically ischemic skeletal muscle.   
 
I present my data in manuscript format. Using histologic techniques, I describe 
changes in the endothelial cell layer of the small arterioles of patients with CLI. I identify 
previously unrecognized distinct morphology of narrowed and occluded lumens. I further 
establish that this pathological change in endothelial cell morphology is associated with 
altered expression and colocalization of key proteins indicating a partial endothelial to 
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mesenchymal transition (EndMT). These findings provide new consequence of EndMT 



















Figure 1.5 Endothelial to Mesenchymal Transition Mediated by TGFb Signaling  
 
EndMT is activated by binding of the TGFb ligand to the TGFb Type II Receptor, which 
will phosphorylate the TGFb Type I Receptor, which will in turn phosphorylate the 
SMAD2/3 complex.  SMAD2/3 will then form a heteromeric complex with SMAD4 and 
translocate into the nucleus. The SMAD complexes can then activate expression of 
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2  CHAPTER 2:  
MICROVASCULAR STENOSIS IN CRITICAL LIMB ISCHEMIA: ROLE OF 
PARTIAL ENDOTHELIAL TO MESENCHYMAL TRANSITION  
 
2.1 Introduction 
Critical limb ischemia (CLI) is a severe manifestation of atherosclerotic peripheral 
artery disease (PAD) that can lead to intractable lower limb pain, infection, and non-
healing ulcers.1  In an effort to improve limb perfusion and retain limb viability, surgical 
and catheter-based procedures are widely employed. Unfortunately, interventional 
success may not translate to clinical improvement.2 Moreover, even with acute clinical 
success, long-term failure from recurrent leg ischemia can ensue.  Up to 66% of patients 
with PAD who have undergone an intervention still require leg amputation.3 
This large burden of refractory PAD suggests that there are additional pathological 
processes, beyond the narrowing of the large and medium-sized feeder arteries, that 
require attention.  Important in this regard is the state of the microvasculature.  
Microvascular dysfunction in PAD is increasingly appreciated, with evidence for 
decreased nitric oxide signaling,4–6 increased production of endothelin receptors,7 and 
decreased arteriolar vaso-responsiveness ex vivo.5,6 There is also evidence that capillary 
density can fall modestly (~10%) in PAD skeletal muscle,8,9 although other studies have 
identified an increase in capillaries, possibly reflecting an angiogenic response.7,10–13  
Importantly, even if angiogenesis proceeds, the function of the neovessels may be 
abnormal.14   
Notwithstanding these defects, the extent to which impaired microvascular vaso-
responsiveness or a modest decline in capillaries can drive CLI, or be a primary cause of 
failed revascularization procedures, is uncertain. Importantly, much about the 
microvasculature in PAD remains unknown.  This includes the structural attributes of the 
distal arteriolar tree, a critical network that controls flow into the capillary bed.  Despite 
their importance, the small caliber of these intramuscular vessels (diameter <40 µm) 
makes morphometric assessment challenging.  Arterioles of this size are comprised of an 
endothelial cell monolayer, and one or two layers of smooth muscle cells (SMCs). 
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However, whether the fundamental cellular structure of the distal arterioles in CLI is 
altered, and if so, what those changes are, remains unknown. 
Herein, we report the phenomenon of non-atherosclerotic, non-thrombotic 
narrowing of small arterioles within the skeletal muscle of critically ischemic limbs from 
individuals with CLI.   We further identify that the pathological restructuring of these distal 
arterioles arises from partial endothelial to mesenchymal transition (EndMT). The findings 
uncover a previously unrecognized microvascular closure process that could underlie the 




2.2.1 Specimen Collection  
All human tissue samples and patient information were collected with written, 
informed consent from patients using protocols approved by the Western University 
Review Board for Health Sciences Research Involving Human Subjects and in 
accordance with the 1964 Declaration of Helsinki. Specimens were collected from the 
skeletal muscle of 10 individuals (6 female, 4 male) with CLI, immediately following below 
or above knee amputation (9 bellow-knee and 1 above-knee amputation). For each 
patient, skeletal muscle specimens 1 cm by 1 cm by 0.5 cm were harvested from both the 
proximal and distal tibialis anterior muscle and/or the gastrocnemius muscle, yielding 24 
samples in total. 
Non-PAD muscle specimens were collected from 6 individuals (4 female, 2 male) 
without PAD or muscle diseases. Two specimens were from the tibialis anterior muscle 
(purchased from Amsbio following institutional review board approved protocols) and four 
specimens were collected by needle biopsy of the vastus lateralis within 24-hrs of death.  
 
2.2.2 Histology and Immunostaining   
 Skeletal muscle samples were fixed in 10% formalin for 48 hours, embedded in 
paraffin, and 5-µm thick cross-sections were stained with hematoxylin and eosin and 
Mason’s trichrome.  For immunofluorescence detection sections, were subjected to heat-
mediated antigen retrieval with citrate buffer.  Endothelial cells were identified using one 
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of two different anti-CD31 antibodies, selected to enable double and triple immuno-
labeling as required. Smooth muscle cells (SMCs) were likewise detected using one of 
two anti-smooth muscle (SM) a-actin antibodies, to enable appropriate combinatorial 
immuno-labeling.  The antibodies employed and the optimized combinations are 
delineated in Appendix B and C.  Nuclei were visualized with 4’,6-diamindino-2-
phenylindole (DAPI) Fluoromount-G (SouthernBiotech, 0100-020).14 Fluoresce images 
were acquired using a Nikon A1 hybrid laser-scanning confocal microscope (Galvano 
scanning, lasers 405, 488, 561, and 640 nm excitation wavelengths, as appropriate) using 
NIS Elements software. Microvascular density quantification was obtained using the BX-
51 with RETIGA EXi Mono 12-bit camera (QImaging) and captured with Northern Eclipse 
(EMPIX Imaging Inc.). Fluorescent signals were quantified using Leica Aperio VERSA 
Fluorescence Pathology Scanner (40x objective, z-stack range 1.2 µm with a step size of 
0.2 µm). Specific arteriolar morphology quantification was quantified with Carl Zeiss 
Imager M2m microscope and AxioCam HRm camera captured by AxioVision (Zeiss) 
Software. Bright field images were scanned using Leica Aperio AT2 bright field scanner 
(20x objective).  
 
2.2.3 Analysis of Skeletal Muscle Pathology  
Full section scans of hematoxylin and eosin and Mason’s trichrome-stained muscle 
tissues were obtained using a Leica Aperio AT2 bright field scanner.  Scanned sections 
were evaluated using Aperio ImageScope slide viewing software (Leica Biosystems) for 
myocyte atrophy, myocyte degeneration, central or internal nuclei, interstitial 
inflammation, and endomysial fibrosis. Myocyte atrophy was determined by hematoxylin 
and eosin staining and assessed based on shrunken myofibers with either rounded or 
sharply angular cross-sectional borders.  Myocyte necrosis was based on pale eosin 
staining and mononuclear cell infiltration.  The interstitial pathological attributes 
(inflammation and fibrosis) were ranked on a severity scale of 0 – 3.  The myofiber 
attributes (atrophy and necrosis) were categorized on area scale of + to +++, 
corresponding to <30%, 30-60%, or >60% of tissue section area, respectively. Internal 
nuclei were identified as present or not.  
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2.2.4 Analysis of Capillary and Arteriole Density 
Capillary density was quantified in 5-10 equally spaced, randomly selected, 60x 
objective fields from all samples using ImageJ (NIH). Capillaries (<8 µm in diameter) were 
identified using CD31 immunostaining.  Arterioles (8-60 µm in diameter) were identified 
in sections co-immunolabeled with CD31 and smooth muscle (SM)-a-actin.   
 
2.2.5 Analysis of Arteriolar Morphometry 
Arteriole (8-60 µm in diameter) morphology was quantified from sections imaged 
by widefield microscopy (Carl Zeiss Imager M2m microscope) with AxioVision (Zeiss) 
Software. The lumen area (area within the inner endothelial cell border, µm2) and vessel 
size (circumference at the outer endothelial cell border, µm) of all cross-sectioned 
arterioles were measured from 8-15 equally spaced, randomly selected, 40x objective 
fields of view of CD31 stained sections, using ImageJ (NIH). Fractional endothelial cell 
area was defined as the endothelial cell area divided by the area bound by the outer 
endothelial cell border.  All endothelial cell measurements were made manually and 
based on individual CD31 channel. To establish the range of fractional endothelial cell 
areas within non-PAD arterioles, and recognizing this would vary depending on arteriolar 
size, a 90% prediction band was generated (see Statistical Analysis). Arterioles were 
considered to have lumens narrowed by endothelial cells if the fractional endothelial cell 
area was above the 90% prediction band. The endothelial cell nuclei aspect ratio 
(tangential and orthogonal to the vessel border) was determined from DAPI-stained 
tissues and measured using ImageJ (NIH).  
 
2.2.6 Analysis of N-cadherin and EndMT  
The mean intensity of N-cadherin signal in CD31 positive endothelium of arterioles 
was measured from 10-15 equally spaced, randomly selected, 40x objective fields of view 
using ImageJ (NIH).  All sections were imaged by Carl Zeiss Imager M2m microscope 
and captured under identical imaging parameters with AxioVision (Zeiss) Software. 
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To quantify S100A4 and Snail expression, the respectively immunostained slides 
were scanned (Leica Aperio VERSA) to cover approximately 25 mm2 of tissue. The 
percentage of arterioles positive for either S100A4 or Snail, each co-localizing with CD31, 
was determined from a mean of 35 randomly selected arterioles per tissue sample. The 
proportion of S100A4- or Snail-positive arterioles was categorized based on whether the 
arteriole had a narrowed lumen or open lumen, based on luminal closure criteria 
described above.  
 
2.2.7 Assessment of TGFb Signaling In Situ 
For quantification of TGFb1 expression and abundance of activated, nuclear 
pSMAD2/3, immunostained slides were scanned (Leica Aperio VERSA).  The intensity of 
TGFb1 staining in arterioles was measured from a mean of 25 randomly selected vessels 
per sample. The mean pixel intensity and event area was measured using the Aperio 
Area Quantification FL Algorithm to calculate the integrated intensity of TGFb1 intensity. 
The integrated density (product of the mean pixel intensity and event area for each vessel) 
was averaged for each sample.  For the TGFb co-receptor, Endoglin, sections were 
imaged using laser scanning confocal microscopy and qualitatively assessed. 
The percentage of arterioles with CD31-positive endothelial nuclei containing 
pSMAD2/3 foci was determined for arterioles. A mean of 25 randomly selected vessels 
per sample from the scanned tissue images were evaluated and endothelial pSMAD2/3-
positive arterioles categorized based on lumen caliber, as above.  
 
2.2.8 Statistical Analysis  
All data were non-normally distributed, as assessed using D’Agostino and Pearson 
omnibus normality test, and therefore are presented as median and interquartile range 
(IQR). Comparisons of two groups were evaluated by Mann-Whitney test (non-paired 
analysis), or Wilcoxon matched-pairs test (paired analysis). Multiple (non-parametric) 
comparisons of lumen area of arterioles of different calibers were corrected using the 
Bejamini-Hochberg procedure to control the false discovery rate at a level of 0.05. To 
define an upper limit for the EC area of a normal arteriole of a given size, we plotted the 
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fraction of area occupied by the endothelial cells against the area bound by the outer 
endothelial cell border in non-PAD arterioles (20-60 µm in outer EC circumference, n = 
45 arterioles). Arterioles from the CLI samples were determined to have a thickened 
endothelial cell monolayer with a narrowed lumen if the factional endothelial cell area fell 
above the upper 90% prediction band. Relationships between skeletal muscle pathology 
and arteriole lumen narrowing was tested using a multiple linear regression analysis.  
 
2.3 Results 
2.3.1 Clinical Characteristics  
To elucidate the microvascular pathology in skeletal muscle in individuals with 
critical limb ischemia (CLI), 24 muscle samples were collected from below or above-knee 
amputation specimens of 10 patients (6 female, 4 male).  Demographic and clinical 
features are depicted in Table 2.1.   All PAD patients had a Rutherford category six level 
of ischemia and the mean age was 65±16 years.  Eighty percent of patients had a history 
of smoking, 20% had type 1 diabetes, and 60% had type 2 diabetes.  Half of the patients 
had prior revascularization procedures on the amputated limb (Table 2.1).  Lower-limb 
muscle specimens from six individuals (4 females, 2 males, mean age 52±17) without 
PAD were also studied.   
 
2.3.2 Diverse Pathology in the Skeletal Muscle of Individuals With CLI  
Hematoxylin and eosin and Mason’s trichrome stains revealed that all 24 CLI 
samples had evidence for myofiber atrophy, evidenced by shrunken myofibers with either 
rounded or sharply angular cross-sectional borders (Figure 2.1). This contrasted with the 
polygonal cross-sectional morphology, with less angular corners, of myofibers in non-
PAD samples (n = 6).  Overt myofiber necrosis was found in 18 of 24 samples (from 9 of 
10 patients). As well, 16 of 24 samples displayed at least one myofiber with a centralized 
or internal nucleus, suggesting a degree of myocyte regeneration.  Inflammatory cell 
infiltration into the endomysium compartments was evident in 18 of 24 samples, with all 
patients having at least one muscle region with interstitial inflammation. Fibrosis was 






Table 2.1  Cohort Demographics  
 
 
*T1 – Type 1 diabetes, T2 – Type 2 diabetes 










1 M 60 N Y Y Gastrocnemius 
2 F 31 N Y Y Gastrocnemius 
3 M 57 T1 Y N 
Gastrocnemius 
Tibialis Anterior Proximal 
Tibialis Anterior Distal 
4 M 72 T1 Y N Gastrocnemius 
5 F 79 T2 N Y 
Gastrocnemius 
Tibialis Anterior Proximal 
Tibialis Anterior Distal 
6 F 68 T2 Y N 
Gastrocnemius 
Tibialis Anterior Proximal 
Tibialis Anterior Distal 
7 M 90 T2 Y N 
Gastrocnemius 
Tibialis Anterior Proximal 
Tibialis Anterior Distal 
8 F 74 T2 Y Y 
Gastrocnemius 
Tibialis Anterior Proximal 
Tibialis Anterior Distal 
9 F 67 T2 N Y 
Gastrocnemius 
Tibialis Anterior Proximal 
Tibialis Anterior Distal 
10 F 50 T2 Y N 
Gastrocnemius 
Tibialis Anterior Proximal 











Figure 2.1 Histopathology of Human Skeletal Muscle in Patients with CLI  
 
A-C. Hematoxylin and eosin-stained sections of a non-PAD muscle (A, vastus lateralis), 
and CLI muscles (B, patient 1 gastrocnemius, C, patient 3 tibialis anterior).  CLI muscle 
tissues contain angular, shrunken myofibers (asterix), interstitial inflammation (arrow), 
central nuclei (arrow head), severe necrosis and degeneration (x), and infiltrating 
inflammatory cells (black arrow). D-F. Mason’s trichrome-stained sections of a non-PAD 
muscle (D, vastus lateralis), and CLI muscles (E and F, tibialis anterior, patient 7 and 
patient 3).  The latter demonstrate mild interstitial fibrosis and severe scarring and fibrosis, 
respectively. Images were captured with Olympus BX-51 using Northern Eclipse (EMPIX 





pathological findings was variable, both between patients and among different samples 
from the same patient (Table 2.2).  
 
2.3.3 Capillary and Arteriole Densities are Increased in the Skeletal Muscle 
of Individuals with CLI  
To evaluate the skeletal muscle microvascular content, sections were double-
immunostained for the endothelial cell marker, CD31, and the smooth muscle cell marker, 
smooth muscle a-actin (Figure 2.2 A-B, Figure 2.3 A-B).  Notably, capillary density (< 8 
µm diameter) in the CLI muscles was 1.8-fold higher than that in the non-PAD muscles 
(*p=0.009, Figure 2.2 C). Interestingly, the density of small arterioles (8-60 µm diameter) 
was also significantly increased in CLI samples (*p=0.0002, Figure 2.3 C). These findings 
suggest that, rather than there being a net loss of microvessels, the CLI musculature 
underwent an angiogenic response.  
 
2.3.4 Arteriolar Stenosis: Endothelial Cell Rounding and Thickening  
While scrutinizing the microvascular morphology, we observed small arterioles 
within CLI muscle samples in which the endothelial cells abnormally encroached the 
lumen. As illustrated in Figure 2.4 A, double immunostaining for CD31 and smooth muscle 
a-actin revealed a range of small arteriolar morphologies in CLI skeletal muscle. This 
included arterioles with flattened endothelial cells and an open lumen, arterioles with more 
rounded endothelial cells and a narrowed lumen, and arterioles with lumens completely 
occluded by bulky endothelial cells. Narrowed or occluded lumens were mostly 
appreciable in arterioles ≤20 µm in diameter (as assessed from the outer endothelial cell 
border).  
Quantitative analysis revealed that for a given arteriolar size, based on the outer 
endothelial cell circumference, the lumen area of PAD arterioles was significantly less 
than that of non-PAD arterioles, and reduced by at least 40% (Figure 2.4 B). As well, the 
area of the endothelium, expressed related to the area bounded by the outer endothelial 
cell border was 1.2-fold greater (*p<0.0001) for arterioles in the skeletal muscle of CLI 



















Figure 2.2 Increased Capillary Density in the Skeletal Muscle of Patients with CLI  
 
A-B.  Fluorescence micrographs of human skeletal muscle immunostained for CD31 
showing capillaries (arrows) between myofibers (dotted lines) in a non-PAD muscle (A, 
tibialis anterior) and an increased capillary density in a CLI muscle (B, patient 8, 
gastrocnemius). C.  Graph of data from all muscle samples showing increased capillary 
density in CLI skeletal muscle (n=6 non-PAD samples; n=24 CLI samples, *p=0.0049). 


















Figure 2.3 Increased Arteriole Density in the Skeletal Muscle of Patients with CLI  
 
A-B, fluorescence micrographs of human skeletal muscle immunostained for CD31(red) 
and SM a-actin (green) showing arterioles (arrows) in a non-PAD muscle (A, vastus 
lateralis) and an increased arteriole density in CLI muscle (B, patient 5, tibialis anterior). 
C.  Graph of data from all muscle samples showing increased arteriole density in CLI 
































Figure 2.4 Arteriolar Stenosis in CLI muscle and its association with Endothelial 
Cell Rounding and Thickening 
 
A.  Confocal microscope image projections of arterioles in human skeletal muscle 
immunostained for CD31(red) and SM a-actin (green) (~ 4.5 µm z stack, 0.125 µm steps).  
Upper row depicts arterioles of sizes corresponding to distal non-terminal arterioles and 
lower row depicts smaller arterioles corresponding to terminal arterioles.  Non-PAD 
arterioles have a flattened endothelial monolayer and open lumen.  In CLI arterioles, the 
endothelial monolayer can be flattened, or thickened with endothelial cell re-orientation, 
resulting in a narrowed or entirely occluded lumen.  (See online video supplement, 
Appendix D). B.  Quantitative data for lumen size of non-PAD and CLI arterioles (area 
within the inner endothelial cell border), binned based on overall vessel size 
(circumference at the outer endothelial cell border). (n=45 non-PAD arterioles, n=391 CLI 
arterioles, *p=0.0014).  C.  Fractional endothelial cell area (endothelial cell area divided 
by the area bound by the outer endothelial cell border) in small arterioles (n=45 non-PAD 
arterioles, n=391 CLI arterioles, *p<0.0001). D. Graph of endothelial cell orientation, 
determined from endothelial cell nucleus aspect ratio (n=119 non-PAD endothelial cells, 
n=1450 CLI endothelial cells, *p<0.0001).   
 51 






















































































lumen narrowing. The endothelial cells themselves were rounded and protruding into the 
lumen of the vessel. This was associated with reorientation of the endothelial cell nucleus. 
The nuclear aspect ratio (tangential and orthogonal to the vessel border) was 1.9 in non-
PAD arterioles and 1.2 (*p<0.0001) in CLI arterioles (Figure 2.4D). 
 To quantify the prevalence of pathological arteriolar narrowing, we established a 
90% prediction band based on arterioles (n=45) within skeletal muscle of non-PAD 
patients (endothelial cell area vs vessel area). This revealed that 9% of the small 
arterioles within skeletal muscle of patients with CLI showed a complete occlusion, 33% 
had narrowed lumens, and 58% had an open lumen.  Multiple linear regression analysis 
did not reveal a relationship between any myofiber pathology and proportion of affected 
arterioles in a given sample (p>0.138).   
 
2.3.5 Obstructive Endothelial Cells Have Increased and Atypically Localized 
N-cadherin  
N-cadherin is diffusely expressed in the membrane of microvascular endothelial 
cells and participates in endothelial cell-mural cell anchorage.15,16 Given the striking shift 
in endothelial cell morphology in arterioles of CLI muscle, including greater contact area 
between endothelial cells, we asked if the content or distribution of N-cadherin was 
altered. We double-immunolabeled sections for CD31 and N-cadherin. In the arterioles 
of non-PAD muscle, we observed weak, diffuse signals of N-cadherin in endothelial cells 
(Figure 2.5 A), consistent with previous reports.15 However, there were marked 
differences in endothelial cells of CLI arterioles. First, the mean N-cadherin content was 
increased by 2.5-fold (*p=0.0007) (Figure 2.5 A, B). As well, among CLI arteriole 
endothelial cells, the N-cadherin abundance was higher (1.3-fold, *p=0.0001) in those 
with a narrowed or occluded lumen than those CLI arterioles that still maintained an open 
lumen (Figure 2.5 C).  
Also striking was that N-cadherin was found concentrated and localized at 
endothelial cell-cell junctions. This was evident at the lateral interface between adjacent 
endothelial cells and also at the apical interface of two opposing and contacting 














Figure 2.5 Endothelial Cells in Stenotic Arterioles Have Increased Expression and 
Apical and Junctional Localization of Mesenchymal Marker N-cadherin  
 
A, Confocal micrographs of human skeletal muscle arterioles immunostained for CD31 
(red) and N-cadherin (green). Whereas the N-cadherin signal is diffuse in the endothelial 
cells of the non-PAD arteriole, there is enhanced N-cadherin signal in the endotheila cells 
of the CLI arterioles, with pronounced localization at both side-to-side and apex-to-apex 
intercellular junctions (middle row, arrows) and also at the apex of inwardly protruding 
endothelial cells that have fully occluded the arteriole (bottom row).  B-C.  Plots of N-
cadherin signal in endothelium of non-PAD and CLI arterioles (B, n=6 non-PAD samples; 
n=24 CLI samples, *p=0.0103) and endothelium of CLI-open lumen and CLI-narrowed 

























































finding suggested an active role for N-cadherin junctions in occluding arterioles in CLI 
limbs. Intriguingly, apical endothelial cell N-cadherin complexes were also found in 
arterioles in which endothelial cells protruded well into the lumen but without fully 
contacting the opposing endothelial cell.  
 
2.3.6 Obstructive Endothelial Cells Have Undergone a Partial Endothelial to 
Mesenchymal Transition  
In addition to its role in cell-cell adhesion, N-cadherin is known to mark the process 
of EndMT.17  Therefore, we next determined if the morphologic change in endothelial cells 
within the arterioles was indeed associated with a partial EndMT. For this, we 
immunolabeled the skeletal muscle sections for CD31 to identify the endothelium along 
with the mesenchymal cell marker S100A4, and the EndMT-related transcription factor, 
Snail. Each of these markers were evaluated for their immunoreactivities in endothelial 
cells of the non-PAD and CLI specimens. 
There was a 2-fold increase in the number of arterioles in the CLI muscle which 
exhibited diffuse S100A4 staining compared to non-PAD muscles (*p=0.0059) (Figure 2.6 
A, B). Additionally, the percentage of S100A4-positive vessels was further increased in 
the CLI narrowed lumen vessels compared to the open lumen vessels (7.4-fold 
*p<0.0001) (Figure 2.6 C). 
Similarly, endothelial cells within the non-PAD arterioles were mostly negative for 
nuclear transcription factor staining with Snail. However, 75% of the arterioles studied 
within the CLI muscle showed punctate, nuclear Snail staining (*p=0.0002) (Figure 2.7 A, 
B). Further analysis showed that there was a 2.6-fold increase (*p<0.0001) in the 
percentage of vessels expressing nuclear Snail when comparing the CLI narrowed lumen 
vessels to the open lumen vessels (Figure 2.7 C).  
 Together, these findings strongly indicate the process of partial EndMT in the 
small intramuscular arterioles within skeletal muscle of CLI patients, associated with 












Figure 2.6 Rounded Endothelial Cells Have Expression of Mesenchymal Markers 
S100A4  
 
A.  Confocal micrographs of human skeletal muscle arterioles immunostained for CD31 
(red) and S100A4 (green), showing cytoplasmic S100A4 signal in endothelial cells of a 
CLI arteriole with a narrowed lumen (arrow), but not in endothelial cells of control, non-
PAD arteriole.  B-C. Graphs showing the proportion of endothelial S100A4-positive 
arterioles in non-PAD and CLI samples (B, n=6 non-PAD samples; n=24 CLI samples, 
*p=0.0059) and the proportion of S100A4-positive arterioles in CLI-open lumen and CLI-










































































Figure 2.7 Rounded Endothelial Cells Have Expression of EndMT Transcription 
Factor Snail1 
A. Confocal micrographs of human skeletal muscle arterioles immunostained for CD31 
(red) and Snail1 (green), showing punctate Snail1 signals in the nucleus of endothelial 
cells in a CLI arteriole with a narrowed lumen (arrow).  B-C. Graphs showing the 
proportion of endothelial Snail1-positive arterioles in CLI samples (B, n=6 non-PAD 
samples; n=24 CLI samples, *p=0.0002) and the proportion of Snail1-positive arterioles 































































2.3.7 Obstructive Endothelial Cells Display Increased Transforming Growth 
Factor Beta (TGFb) Signaling  
TGFb signaling regulates endothelial cell phenotype and plays an important role 
in the progression of EndMT18 process by activating expression and increasing the activity 
of EndMT transcription factors.19 To determine if endothelial cells in CLI arterioles were 
receiving TGFb signals, sections were immunolabeled with pSMAD2/3. There was 
evidence for pSMAD2/3 in both non-PAD and CLI arterioles. However, there was a 1.4-
fold increase (*p=0.0078) in the punctate, endothelial cell nuclear staining in the CLI 
samples (Figure 2.8 B). Notably, the CLI arterioles with a narrowed lumen showed a 
particularly increased percentage of arterioles positive for pSMAD2/3 (7.9-fold, 
*p<0.0001) (Figure 2.8 C). These findings implicate an enhanced TGFb-induced signaling 
and gene-expression cascade in CLI arterioles.  
 
2.3.8 Transforming Growth Factor Beta (TGFb) Upregulation in CLI 
 To determine the content and location of TGFb ligand in the CLI samples, sections 
were stained for TGFb1. The mean expression of TGFb1 was increased 63-fold in the 
arterioles of CLI samples compared to the non-PAD samples (Figure 2.9 B). Notably, the 
upregulation was primarily found in the smooth muscle cells (Figure 2.9 A). Interestingly, 
this expression pattern was not limited to the arterioles with narrowed lumen but could be 
seen in arterioles with open lumens as well (data not shown). This expression was also 
not limited to the vessels within the 20-60 µm in outer endothelial cell circumference size 
range (data not shown), although for the purposes of this analysis this was the size range 
evaluated. To determine if there was differential receptivity of endothelial cells for TGFb 
signaling between non-PAD and CLI tissues, we stained for the TGFb co-receptor, 
Endoglin. We found qualitative evidence for Endoglin up-regulation in the endothelial cells 















Figure 2.8 Phospho-SMAD 2/3 Activation in Rounded Endothelial Cells 
 
A.  Confocal micrographs of human skeletal muscle arterioles immunostained for CD31 
(red), pSMAD2/3 (green), showing discrete pSMAD2/3 punctate signals in the nucleus of 
endothelial cells within the CLI arteriole (arrow). B-C.  Graphs depicting the percentage 
of pSMAD2/3-positive arterioles in non-PAD and CLI samples (B, n=6 non-PAD samples; 
n=24 CLI samples, *p=0.0078) and in CLI narrowed lumen arterioles compared to those 











































































Figure 2.9 Transforming Growth Factor b1 (TGFb1) Activation in Smooth Muscle 
Cells of CLI Arterioles  
 
A. Confocal micrographs of human skeletal muscle arterioles triple-immunostained for 
CD31 (red), SM a-actin (green), and TGFb1 (white).   There is increased TGFb1 signal 
in the vascular smooth muscle cells of the CLI arteriole (arrow). B.  Graph showing 
substantially increased TGFb1 expression in smooth muscle cells of CLI arterioles (n=6 
non-PAD samples; n=24 CLI samples, *p=0.0002). 
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Figure 2.10 Endoglin Expression in Endothelial Cells of CLI Arterioles 
 
Confocal micrographs of human skeletal muscle arterioles triple-immunostained for CD31 
(red), SM a-actin (green), and Endoglin (white), showing increased Endoglin expression 





2.4 Discussion  
 
Peripheral artery disease is primarily considered a disease of the large vessels. 
While atherosclerosis is the driving process, the microvascular determinants of refractory 
PAD and CLI remain poorly understood.  In this study, we report a novel form of arteriolar 
stenosis in individuals with CLI, wherein the endothelial cells obstruct the lumen. This 
phenomenon was found to arise from pronounced rounding and thickening of endothelial 
cells, a morphological shift that was associated with partial endothelial to mesenchymal 
transition.  Notably, this endothelial cell pathobiology affected the smallest arterioles, 
those less than 20 µm in diameter, with 42% being significantly narrowed and 9% being 
completely occluded.  This high burden of arteriolar closure points to an important, but 
previously unrecognized, process in CLI.  
The finding of arteriolar lumen narrowing due to bulky endothelial cells in patients 
with CLI is remarkably different from the lumen narrowing from atherosclerotic disease.  
The broad phenomenon of arteriolar stenosis is not new and has been recognized in a 
number of conditions. This includes (1) vasculitis,20,21 (2) transplant vasculopathies,23 (3) 
thromboembolic disease,24–26 and (4) cholesterol emboli.21 However, neither leukocyte 
infiltration or fibrinoid changes, hallmarks of vasculitis,21,22,27 were evident on the CLI 
arterioles studied, nor was there evidence for microaneurysms, thrombi or cholesterol 
emboli.   Instead, the rounded and re-oriented microvascular cells themselves, specifically 
the endothelial cells, were occluding the lumen.  
Interestingly, the phenomenon of arteriolar occlusion in individuals with severe 
PAD and CLI has been recognized.  Casting studies in the 1960’s revealed that, in legs 
of individuals with CLI, there were arterioles of diameter 10-100 µm that were seen to be 
occluded.26,28 However the true nature of the casting findings remained unknown and, 
perhaps because of this, the phenomenon appears to have lost traction as a 
pathophysiologic consideration in CLI. Although we cannot be sure if the occluded lumens 
in these early studies were due to endothelial cell plugging, the findings, together with the 
high prevalence of arteriolar obstruction identified in the muscles studied herein, 
consolidate arteriolar obstruction as an entity warranting further investigation. 
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Our finding of EndMT leading to luminal encroachment is a novel outcome of 
EndMT. The classical outcomes of EndMT are endothelial cells gaining invasive abilities, 
delaminating and sprouting or egressing off the vessel wall.17,29 However, evidence is 
emerging that EndMT can exist on a spectrum, where the final expression and cell 
phenotype adopted can vary widely. The concept of partial EndMT reflects this spectrum, 
and is employed when at least one of the key characteristics of complete EndMT is not 
exhibited.30 The obstructing endothelial cells maintained CD31 expression, while 
acquiring mesenchymal attributes indicated by the mesenchymal markers S100A4 and 
Snail, and expressing N-cadherin to a significantly higher extent than control arterioles. 
Intriguingly, in addition to expressing CD31, these altered cells remained on the luminal 
side of the vessel and maintained cell-cell contacts.  Thus, although the phenotype is 
unique, collectively the findings strongly support a phenomenon of partial EndMT.  
The reason why partial-EndMT in the CLI limbs resulted in the inward positioning 
of endothelial cells towards the lumen, in contradistinction from sprouting off the vessel, 
is unknown. It is possible that, in the context of the ischemic and damaged tissue, the 
endothelial cells were effectively trapped on the luminal side of an arteriole thickened by 
extracellular matrix accumulation,31 effectively confining the basal surface of the 
transitioning endothelial cells in place. Thus, the arteriolar constituents could halt or 
otherwise modify the typical progression of EndMT, leading to bulky endothelial cells 
occluding arterioles.   
In addition to the EndMT marker upregulation in the obstructing endothelial cells, 
we also noted an interesting change in N-cadherin localization. Specifically, N-cadherin 
shifted from a diffuse expression signal, consistent with its dispersion on the endothelial 
cell membrane,15,32 to discrete N-cadherin-containing junctions between adjacent 
endothelial cells and, in some cases, opposing endothelial cells (Figure 2.4a). Typically, 
N-cadherin does not act as a junctional molecule for endothelial cell-endothelial cell 
interactions, a role widely known to be accomplished by VE-cadherin.  Instead, N-
cadherin in the endothelium it is considered to mediate endothelial-mural cell 
interactions.16  This shift in N-cadherin location and function is consistent with the 
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established phenomenon of cadherin switching.16  Importantly, N-cadherin is involved in 
cytoskeletal remodeling, including cortical actin regulation in epithelial cells.33  
The finding of apical N-cadherin in endothelial cells of the occluded or narrowed 
arterioles is also noteworthy. A number of studies have demonstrated an evolutionarily-
conserved apical enrichment of N-cadherin in developing neural tube.  Loss of this N-
cadherin subcellular localization has been associated with defects in neuroepithelial 
morphogenesis, including failed neural tube closure and disrupted neuroepithelial 
cytoarchitecture.34–38  Although these studies were not in endothelial cells, epithelial cells 
have similar characteristics such as polarity, specialized cellular shape and orientation. 
The localization of N-cadherin at endothelial cell junctions could be a new mode of 
cadherin switching. Whether it is associated with a decrease in VE-cadherin remains 
unknown. However, the specific localization of N-cadherin within the occluded arterioles 
strongly suggests both implications for cytoskeletal remodeling, and N-cadherin mediated 
“gluing” of the partially-transitioned endothelial cells, both side-to-side and apex-to-apex 
across the lumen of arterioles.  
Our finding of increased TGFb1 in SMCs of patients with CLI supports TGFb 
signaling pathway-induced EndMT.  It is known that SMCs can increase their TGFb1 
expression in patients with CLI, but the implications of this have yet to be fully 
elucidated.31   The TGFb signaling pathway is a characterized driver of EndMT,17,39 further 
supporting a potential TGFß-arteriolar occlusion axis in patients with CLI. Based on the 
increased nuclear expression of SMAD2/3 in the obstructive endothelial cells, as well as 
the increased expression of co-receptor Endoglin, we propose that TGFb signaling 
constitutes a disease promoting EndMT pathway in CLI.  
There was no correlation found between myofiber damage and the number of 
affected arterioles in a given sample.  However, this is not surprising as the site of hypoxia 
and ischemic damage will be downstream of the site of arteriolar pathology.  It will 
however be interesting to ascertain if partial-EndMT-associated arteriolar stenosis 
proceeds in individuals at earlier stages of PAD. This is particularly important because 
only about 1-2% of patients with intermittent claudication will progress to CLI1 and at 
present it’s not possible to identify which patients will remain stable or escalate to limb-
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threatening ischemia. One could speculate that whether or not stable intermittent 
claudication will escalate to CLI could in part depend on whether the skeletal muscle 
microvasculature is affected by EndMT.  The current findings could also have implications 
for disease treatment, for example strategies that inhibit EndMT or TGFb1 expression in 
the at-risk skeletal muscle.  
In conclusion, evaluating the status of the microvasculature in patients with CLI 
has brought about the discovery of non-atherosclerotic, non-thrombotic narrowing of 
small arterioles.   We further identified that the pathological restructuring of these distal 
arterioles arises from partial EndMT.  The findings uncover a previously unrecognized 
microvascular closure process that could underlie the debilitating ischemic damage of 
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3 CHAPTER 3:   
GENERAL DISCUSSION AND CONCLUSIONS 
 
The findings presented in this thesis provide new insights into the microvasculature 
in the ischemic skeletal muscle of patients with CLI. The skeletal muscle landscape of 
CLI patients was found to be heterogeneous, and the pathology included myofiber 
atrophy and necrosis, interstitial fibrosis and inflammation, and some myofibers with 
internal nuclei. Interestingly, although the skeletal muscle had ischemic injury, both the 
capillary density (< 8 µm diameter) and arteriole density (8 – 40 µm diameter) were 
increased in the skeletal muscle of patients with CLI. Despite this increased 
vascularization, I discovered a pronounced abnormality in the arteriolar wall of these 
vessels. Specifically, 42% of arterioles of 8 – 20 µm diameter had a significantly narrowed 
lumen, with 9% showed complete occlusion. This arteriolar stenosis was caused by 
obstructive, rounded endothelial cells that encroached upon the lumen. Upon further 
investigation, it was established that these bulky endothelial cells had a distinct 
expression of N-cadherin, with a remarkable localization at the apex and endothelial cell-
cell junctions. As N-cadherin is known to mark the process of EndMT,1 I further 
investigated other EndMT markers, specifically S100A4 and Snail. It became evident 
these cells had undergone a partial EndMT. Based on subsequent results from 
immunostaining for pSMAD2/3, TGFb1, and the TGFb co-receptor, endoglin, I propose a 
TGFb receptor/SMAD signaling pathway as a mediator of this newly discovered partial 
EndMT process in CLI (Figure 3.1).  
 
3.1 Microvascular Density in CLI 
For over 50 years, the microvasculature has been considered to be one reason 
why blood flow is impeded in the critically ischemic limb.2 Over the years the 
understanding of the pathology of these small vessels has remained limited and 
controversial. Most studies evaluating the microvasculature in patients with CLI have 
















Figure 3.1 Arteriolar Stenosis caused by Endothelial to Mesenchymal Transition  
 
EndMT is activated by binding of the TGFb ligand to the TGFb Type II Receptor, which 
will phosphorylate the TGFb Type I Receptor, which will in turn phosphorylate the 
SMAD2/3 complex.  SMAD2/3 will then form a heteromeric complex with SMAD4 and 
translocate into the nucleus. The SMAD complexes can then activate expression of 
EndMT genes and increase activity of EndMT transcription factors causing the 
transitioning endothelial cell to round up and protrude into the lumen of the vessel. N-





perfusion.3,4 However, findings have been divergent. Some studies have indicated that 
humans have angiogenic capabilities, showing an increase in the capillary and 
microvascular density in patients with PAD.5–9 Others have shown no change, or a 
decrease in capillary density.10–14 The split field may be attributed to a few factors: (1) 
variability in the control groups used, (2) variability in how microvascular density was 
measured, and (3) patient-specific variability in angiogenesis (which I address below). My 
findings are in accordance with reports that indicated an increase in microvascular 
density. In fact, I found both the capillary density and arteriole density to be significantly 
increased in patients with CLI. 
It should be noted that there is difficulty in obtaining an optimum control 
assessment for PAD limbs. As microvascular density is most accurately measured from 
histology, a tissue biopsy is necessary. While some studies had the opportunity to harvest 
normal controls during lower limb surgery or needle biopsy,6–8,12,13,15–19 others have used 
a proximal region in the same patient as a control.20,21 As we and others have shown, the 
skeletal muscle of patients with CLI is vastly affected and heterogeneous.22–25 Making the 
assumption that the muscle in the proximal region of the patients amputated limb may 
create confounding factors and affect angiogenesis related data. For my study, skeletal 
muscle was harvested from the vastus lateralis of non-PAD individuals. While there will 
remain patient-specific variability in angiogenesis, sampling multiple regions from the CLI 
muscles and using different control individuals will help minimize the effects of muscle 
heterogeneity on my data.   
Capillaries are small and can be difficult to label; therefore, the choice of 
endothelial cell marker can also bring about variability in capillary density measurements. 
Investigators have taken advantage of different endothelial cell markers, for example 
CD31, vWF, or CD34.6–9,12,13,15–19 The most commonly used marker is CD31, which I 
made use of in my study. Moreover, the definition for the microvascular density measured 
has varied. Some measured microvascular density without defining or distinguishing 
between capillaries and small arterioles.7–9 Some measured a capillary to fiber ratio,5,10 
and others evaluated the mean capillary density.6,7,12,13 Although both of these 
assessments act as a measure of angiogenesis, the fiber-type heterogeneity within 
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skeletal muscle requires rigorous procedural attention when selecting histological images 
to avoid sampling bias within any given muscle sample.26  
Despite the above methodological concerns, the extent of angiogenic response in 
patients with PAD has long been the primary and most-widely assessed endpoint. Many 
clinical trials for PAD have been based on capitalizing on the natural process of 
angiogenesis to re-perfuse the ischemic leg. These attempts at therapeutic angiogenesis 
have been met with little success.3 While it is critical to understand the angiogenic 
capabilities of critically ischemic skeletal muscle in humans, the functionality of surviving 
and growing microvessels in ischemic human muscle is equally, if not more, important. 
Studying the cellular and structural components of the microvasculature of these patients 
– whether native or regenerated – is an important starting point to understanding this 
complex disease.  My findings of microvascular density are important in this regard 
because they establish that, despite an abundance of small vessels in the limbs of those 
with CLI, the structure of these vessels, as discussed below, can be profoundly abnormal.  
 
3.2 Arteriolar Stenosis in Critical Limb Ischemia  
Through vessel by vessel examination of the cellular structure of the microvascular 
wall in the chronically ischemic skeletal muscle, I discovered a novel form of arteriolar 
stenosis, wherein the endothelial cells obstructed the lumen. The finding of arteriolar 
stenosis due to bulked-up endothelial cells occluding the lumen in humans constitutes 
previously undescribed mode of arteriolar pathology. To date, arteriolar stenosis has been 
recognized to arise from: (1) vasculitis;27,28 (2) transplant vasculopathies;29 (3) 
thromboemboli;30,31 and (4) cholesterol emboli.28 Small vessel vasculitis refers to the 
inflammation of the blood vessel walls and plays a role in many diseases such as Churg-
Strauss syndrome, microscopic polyangiitis, and polyarteritis nodosa.27,28 Vasculitis can 
be histologically characterized by granulomatous inflammation, leukocyte infiltration, and 
fibrinoid changes in the vascular wall.32 Microvasculopathy is the term generally used to 
denote a non-inflammatory arteriolar stenosis and can originate from immune complex 
deposition, can be associated with tortuosity of small vessels, and organ transplant.28,33 
Embolic stenosis can be caused by thrombosis or cholesterol.34 The microvascular 
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pathology that I have discovered is entirely novel in humans in that it is the native 
microvascular cells, specifically the endothelial cells, that are occluding the lumen. There 
was neither inflammatory cells nor emboli involved. 
A search of the literature has revealed one study that has detected endothelial cell 
pathology that appears similar to what has been noted here. Specifically, a group in 
Montreal, Quebec has identified endothelial cell hypertrophy and microvascular occlusion 
in horses. Specifically, Dubuc et al. studied abnormal wound repair in horse limbs, a 
phenomenon termed proud flesh that is characterized by excessive fibroplasia and 
scarring, also known as hypergranulation.35 Their group found that there were 
microvessels within the granulation tissue in which the surface area of the endothelial 
cells was increased and the lumen was occluded.35 While the reason for this unusual 
endothelial cell morphology was not proposed, they suggested the cells may be 
apoptosis-resistant. Although this finding was in equine proud flesh and not human PAD, 
granulation tissue can be associated with tissue hypoxia, ischemia, and delayed wound 
healing. Additionally, other studies have shown an increase in TGFbRI and TGFbRII in 
the endothelium of vessels in proud flesh of horses.36 This is an interesting parallel to our 
findings of arteriolar stenosis in patients with CLI. It is possible that the hypertrophied 
endothelial cells that were found in equine proud flesh underwent a partial EndMT 
process homologous to what I have observed in CLI.  
It should also be noted that the phenomenon of arteriolar stenosis in human PAD 
has previously been identified, but in a limited way and without mechanistic data. In 1967, 
Margret Conrad determined that some arterioles from 30 – 100 µm in diameter in patients 
with CLI showed occlusion. This was based on casts made of the vasculature.2  With her  
method, it was not possible to determine the nature of occlusion, although she suggested 
it may be small thrombi.2 It is interesting to speculate that the truncated arterioles that 
Conrad showed in her casting images were due to the endothelial cell obstruction in the 





3.3 N-cadherin in Critically Ischemic Arteriolar Endothelial Cells 
The bulky endothelial cells I studied in the arterioles of CLI patients had an 
interesting N-cadherin localization. Specifically, rather than the  diffuse expression within 
the endothelial cell membrane that has been well-documented in endothelial cells in 
situe,37,38 the localization shifted to discrete N-cadherin junction complexes between 
adjacent endothelial cells and, in some cases, between opposing endothelial cells. This 
is interesting because N-cadherin typically does not concentrate at endothelial cell 
junctions and does not act as a cadherin for endothelial cell-endothelial cell interactions. 
That role is widely known to be accomplished instead by VE-cadherin. N-cadherin, on the 
other hand, is considered to play a role in endothelial-mural cell junctions.39 Cadherin 
switching – i.e. from one type of cadherin to a different one – is understood to play a role 
in EMT as well as in endothelial cell invasiveness and cell motility.39 The altered 
localization of N-cadherin forming at endothelial cell junctions may be a form of cadherin 
switching. Whether it is associated with a fall in VE-cadherin is not yet known. However, 
the findings strongly suggest that there is N-cadherin-mediated gluing of the partially-
transitioned endothelial cells both side-to-side and apex-to-apex across the lumen of 
arterioles.  
N-cadherin is also involved in cytoskeletal remodeling through actin regulation.40 
Leonard et al. showed that the assembly of mature N-cadherin junctions along cell-cell 
interfaces preceded the organization of a cortical actin cytoskeleton of lens epithelial cells 
in the embryonic chicken.40 A number of studies have demonstrated an evolutionarily-
conserved apical enrichment of N-cadherin in the developing neural tube, and loss of this 
N-cadherin subcellular localization has been associated with defects in neuroepithelial 
morphogenesis, typically including failed neural tube closure and disrupted 
neuroepithelial cytoarchitecture.41–45 Although these studies were not in endothelial cells, 
epithelial cells have some similarities to endothelial cells, particularly in respect to their 
polarity and specialized cellular shape and orientation. It would be interesting to further 
investigate the role of N-cadherin on cytoskeletal remodeling of endothelial cells to see if 
increased junctional N-cadherin is associated with cytoskeletal remodelling that mediates 
the rounded and bulky endothelial cells (see Future Directions Section 3.6).   
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3.4 Partial Endothelial to Mesenchymal Transition in CLI Arterioles  
In addition to discovering N-cadherin junctional localization in obstructive 
endothelial cells, there was also a general increase in N-cadherin expression. Increased 
N-cadherin expression is linked with EndMT.1 Accordingly, I further investigated the 
expression profile of EndMT markers in these endothelial cells and found that they had 
increased expression of S100A4 and Snail. Collectively, these finding provide strong 
evidence for partial EndMT in CLI arterioles.  
The classical outcomes of EndMT are endothelial cells gaining invasive abilities 
leading to delaminating and sprouting or egressing off the vessel wall.1,46 However, 
evidence is emerging that EndMT can exist on a spectrum, where the final endothelial 
cell phenotype can vary widely following the transition. For this reason, the concept of 
partial EndMT has been developed, and employed to denote when at least one of the key 
characteristics of complete EndMT are not exhibited. This could include failure to lose 
cell-cell contacts.47 Not only is our discovery the first time EndMT (either partial or 
complete) has been pathologically associated with PAD, but the inward bulging of the 
endothelial cells is also a new morphologic feature of endothelial cells undergoing a 
partial-EndMT.  
Typically, pathological assessment of EndMT has relied on co-staining of 
endothelial cell markers and mesenchymal cell markers and this is the approach I have 
taken. However, this approach has some limitations: (1) immunostaining cannot identify 
EndMT if the cells are so far along in the transition that they have entirely lost their 
endothelial cell markers; (2) immunostaining reliability is dependent on antibody 
specificity and sensitivity; (3) immunostaining interpretation is subject to overlay errors in 
light microscopy, where the superimposition of two cells can be misinterpreted as signal 
from one cell; and (4) immunostaining is limited in the number of proteins that can be 
assessed.48  
Due to the nature of our experiments and tissue collection, we are limited to some 
extent by these factors. Primarily, we cannot determine if the endothelial cells that have 
undergone a partial transition will continue on to eventually delaminate and fully 
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differentiate “out” of the endothelial cell state. However, we propose this is unlikely 
because of their luminally-inward shift. We note that laser capture of these obstructive 
endothelial cells followed by RNA sequencing would allow genome-wide characterization 
of these cells and determine if there is a spectrum within the transitioning cells (see Future 
Directions Section 3.6). However, this would be a huge technical challenge. Ultimately, 
the endothelial cells causing luminal obstruction warrant further study as it would be 
exciting to determine the extent and reversibility of the partial EndMT and occlusion 
processes in ischemic human muscle.  
Finally, it should be noted that although we are reliant on the specificity and 
sensitivity of the antibodies used, the laser scanning confocal microscopy that I employed 
has allowed for z-stacks with 0.125 µm steps. Confocal microscopy allows the recording 
of images at different focal planes, while removing the out-of-focus signal collected. Each 
step acquires an image at that specific focal plane. This in turn enabled 3-dimensional 
reconstructions at high resolution, providing reliable evidence that we are seeing true 
colocalization of cellular markers, as opposed to markers on two superimposed cells (see 
online video supplement, 4.4 Appendix D). This approach was also helpful in ensuring 
the rounded endothelial cells identified were not circulating leukocytes trapped in a lumen, 
which can also express CD31 staining.49 
 
3.5 TGFb Signaling Pathway   
TGFb signaling has recently emerged as relevant to the skeletal muscle in the legs 
of patients with PAD. For example, Ha et al. explored this phenomenon with regard to 
fibroblast accumulation and collagen deposition.50  Corroborating my findings, they noted 
that TGFb1 was strongly expressed specifically in the SMCs of the microvessels. They 
suggested that this is a result of chronic hypoxia causing damage to the muscle myofibers 
which could induce the SMC of the microvessels to increase their TGFb1 expression.50  
As noted above, the classical outcomes of EndMT are endothelial cells gaining 
invasive abilities resulting in delamination, sprouting or egressing off the vessel wall.1,46 
My finding of a partial EndMT resulting in rounded endothelial cells moving toward the 
centre of the lumen is unique. I venture that these endothelial cells are undergoing a form 
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of a failed EndMT in response to increased TGFb1 expression.  It is understood that PAD 
results in fibrosis of microvessels with both collagenous thickening of the capillaries and 
muscularization and fibrosis of normally non-muscularized microvessels.8,50,51 I speculate 
that this thickening and fibrosis effectively traps the transitioning endothelial cells within 
the arteriole lumen, halting or modifying the typical progression of EndMT and resulting 
in an occluded vessel.  
My finding of increased content of the ligand TGFb1 in SMCs and increased 
pSMAD2/3 and Endoglin in endothelial cells in muscle of patients with CLI supports TGFb 
signaling pathway induced-EndMT. TGFb has been recognized as a dominant driver of 
EndMT during development and pathogenesis of a number of human diseases, including 
fibrosis of multiple organs, pulmonary arterial hypertension, brain vascular malformation, 
and transplant vascular graft rejection.48 It is interesting to note that vascular SMC can 
have increased TGFb1 in patients with CLI, but the implications of this have yet to be fully 
elucidated.52 While the causal role of the TGFb signaling pathway in EndMT in ischemic 
muscle of patients with CLI requires further investigation using ex vivo cell or animal 
models, my current study provides strong evidence for an intriguing novel model of 
EndMT driven by paracrine/juxtacrine signaling of SMCs.    
 
3.6 Future Directions  
The findings of (1) arteriolar stenosis by obstructing endothelial cells; and (2) the 
association of partial-EndMT in CLI both require further investigation because of their 
novelty and importance with regard to delineating the mechanisms of the disease.   
To further study the obstructing endothelial cells, it is important to further 
characterize their expression. As discussed previously, immunohistochemistry has 
limitations on the number of markers that can be analyzed. Although laser capture 
followed by RNA sequencing would be a technically difficult experiment, it would allow 
genome-wide characterization of these cells and determine if there is a spectrum within 
the transitioning cells.  
It is also important to further investigate the role of N-cadherin on cytoskeletal 
remodeling of endothelial cells to see if increased junctional N-cadherin is associated with 
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cytoskeletal remodeling that mediates the rounded and bulky endothelial cells. 
Additionally, the concept of N-cadherin-mediated “gluing” of opposing endothelial cells 
raises entirely new questions regarding adherens junctions, warranting further 
exploration. It would also be important to determine if the vessel occlusion is reversible, 
as this could implicate possible new therapeutic strategies in some CLI patients. This 
assessment would require developing an in vivo or microfluidic model of arteriolar closure 
caused by endothelial cells.  
The association of EndMT in CLI is new and raises some important clinical 
questions. Only about 1-2% of patients with intermittent claudication will progress to CLI53 
and at present it is not possible to predict the patients in whom disease progression will 
escalate and those in whom disease severity will remain constant.  I propose that 
progression of a patient’s diagnosis of intermittent claudication to CLI could, in part, be 
dependent on the local TGFb environment of the skeletal muscle. If unregulated signaling 
from the mural cells is activated, this could promote partial EndMT and microvessel 
plugging. This, in turn, could be an important driver of high-grade ischemia in the leg, over 
and above flow reduction from upstream narrowing, changing stable PAD to CLI. Studies 
in animal models or in humans that allow for tracking the progression from less severe 
PAD with open arterioles to endothelial-plugged arterioles would be important in 
delineating this proposed ischemic transition. Also, developing a biomarker, either 
imaging or biochemical, that would implicate the endothelial cell plugging process could 
stand to be an indicator of distal arteriolar health and potentially help clinical decision-
making.   
Finally, in addition to TGFb1 signaling, it is understood that EndMT can be flow-
mediated.54,55 This suggests a potential additional factor contributing to the occurrence of 
EndMT in CLI.  CLI is fundamentally caused by accumulation of atherosclerotic plaque in 
the arteries that supply the lower leg.53  This results in a decrease in overall perfusion to 
the distal vessels in the limb, inducing a low-flow environment. Endothelial cells are 
responsive to flow rate and have been shown to undergo EndMT under both low-flow and 
turbulent flow conditions, for example in atherosclerotic plaque found at artery branch 
points.54,55 As CLI is understood to be a low-flow environment. I have considered if flow 
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is a contributing factor to inducing partial EndMT in the arterioles of patients with CLI.  To 
better understand the implication of flow, an endothelial cell-specific flow model, such as 
a microfluidics channel, should be employed to study endothelial cells under varying flow 
rates, and with and without the addition of TGFb1 inhibitor, to better understand the 
conditions under which EndMT is induced and results in the inward protrusion of 
endothelial cells into the vessel lumen.  
 
3.7 Conclusion 
In conclusion, evaluation of the status of the microvasculature in patients with CLI 
has brought about the discovery of non-atherosclerotic, non-thrombotic narrowing of 
small arterioles. I further identified that the pathological restructuring of these distal 
arterioles arises from partial endothelial to mesenchymal transition (EndMT).  The 
findings uncover a previously unrecognized microvascular closure process that could 
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4.2 Appendix B: Antibody Information  
 
Target antigen Vendor or Source Catalog # 
Working 
concentration 
CD31 (a) Thermo Fisher 
Scientific 
RB-10333-P1 1:50 
CD31 (b) Agilent M0823 1:20 
SM-α-actin (a) Agilent M0851 1:100 
SM-α-actin (b) Novus NB300-978 1:100 
N-Cadherin Novus NB200-592 1:400 
S100A4 Abcam ab41532 1:100 
Snail Thermo Fisher 
Scientific 
14-9859-82 1:50 
TGFb1 Abcam ab92486 1:100 
phospho-SMAD 2 Thermo Fisher 
Scientific 
3108 1:100 
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4.3 Appendix C: Co-Staining Information  
 
Pair 1: CD31 and SM-α-actin 
Primary Antibody Secondary Antibody  
CD31 (a): Rabbit polyclonal  Alexa Fluor 488- conjugated goat anti-
rabbit IgG 
SM-α-actin (a): Mouse monoclonal  Alexa Fluor 546-conjugated goat anti-
mouse IgG 
 
Pair 2: CD31 and N-cadherin  
Primary Antibody Secondary Antibody 
CD31 (b): Mouse monoclonal anti-
CD31  
biotinylated goat anti-mouse IgG 
DyLight 649-conjugated streptavidin 
N-Cadherin: Rabbit polyclonal  Alexa Fluor 488- conjugated goat anti-
rabbit IgG 
 
Pair 3: CD31 and S100A4 
Primary Antibody  Secondary Antibody  
CD31 (b): Mouse monoclonal anti-
CD31 
biotinylated goat anti-mouse IgG 
DyLight 649-conjugated streptavidin 
S100A4: Rabbit polyclonal  Alexa Fluor 488- conjugated goat anti-
rabbit IgG 
 
Pair 4: CD31 and Snail1 
Primary Antibody  Secondary Antibody  
CD31 (a): Rabbit polyclonal  Alexa Fluor 488- conjugated goat anti-
rabbit IgG 
Snail1: Mouse monoclonal 
 
biotinylated goat anti-mouse IgG 
DyLight 649-conjugated streptavidin 
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Pair 5: CD31 and pSMAD2 
Primary Antibody Secondary Antibody  
CD31 (b): Mouse monoclonal anti-
CD31  
biotinylated goat anti-mouse IgG 
DyLight 649-conjugated streptavidin 
pSmad2: Rabbit polyclonal  Alexa Fluor 488- conjugated goat anti-
rabbit IgG 
 
Triplet 1: CD31, SM-α-actin and TGFb1 
Primary Antibody Secondary Antibody  
CD31 (b): Mouse monoclonal anti-
CD31  
biotinylated goat anti-mouse IgG 
DyLight 649-conjugated streptavidin 
SM-α-actin (b): Goat polyclonal Alexa Fluor 488-conjugated donkey anti-
goat IgG 
TGFb1: Rabbit polyclonal  Alexa Fluor 546-conjugated donkey anti-
rabbit IgG 
 
Triplet 2: CD31, SM-α-actin and Endoglin 
Primary Antibody Secondary Antibody  
CD31 (a): Rabbit polyclonal  Alexa Fluor 488- conjugated goat anti-
rabbit IgG 
SM-α-actin (b): Goat polyclonal Alexa Fluor 488-conjugated donkey anti-
goat IgG 









4.4 Appendix D: Legends for Supplemental Video Files  
 
Online Video 4.4.1: Normal arteriole immuostained for CD31 and DAPI counter stained 
for nuclei (confocal 3-dimensional reconstruction, 4.5 µm z stack, 0.125 µm steps) 
 
Online Video 4.4.2: Occluded arteriole immuostained for CD31 and DAPI counter 
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Chevalier Freelance:                     [2012 – present]  
 Freelance performance horse grooming (clipping, braiding, mane pulling,  
 show grooming, bathing, mucking), dog and cat sitting, dog training  
[References available upon request] 
  
 Talbot Animal Hospital:                [Jun 2018 – Jun 2019]  
 Assistant (surgical pack preparations, cleaning and facility maintenance,  
pharmaceutical preparations, care for boarding animals, assisting with  
procedures) and reception duties, (answering phones, billing, checking  
patients in) 
 
Robarts Research Institute:                  [Jun - Sep 2017] 
Summer Studentship: learning laboratory techniques including bright  
field and fluorescence microscopy, confocal microscopy, tissue processing  
and sectioning, immunohistochemistry, and histology techniques  
 
Wingberry Farms:                   [Apr – Jun  2017]
 Groom and Flat rider: Care for (grooming, clipping, bandaging, feed,  
turnout, muck stalls) and exercise horses (hunter/jumper), assist with  
health care decisions and veterinarian procedures for performance horses,  
















































Karen Blum:                    [Jan – Apr 2017] 
 Groom and Flat rider: Care for (grooming, clipping, bandaging, feed,  
turnout, muck stalls) and exercise horses (hunter/jumper), assist with  
health care decisions and veterinarian procedures for performance horses,  
clean and maintain facility and stable, care for family dogs 
 
Tutor Doctor:                           [Jan  – Apr 2017] 
 Tutor: Tutoring high school level math and science. Determining the most  
efficient method of teaching for each individual student, and designing  
lesson plans that cater to their individual learning needs.  
 
Beth Underhill Stables:                [Apr 2016 – Jan 2017] 
 Groom and Flat rider: Care for (grooming, clipping, bandaging, feed,  
turnout, muck stalls) and exercise horses (hunter/jumper), assist with  
veterinarian procedures for performance horses, clean and 
 maintain facility and stable  
 
Ironstone Stables:                               [2008 – Apr 16] 
Coach and Staff: Care for, exercise and train horses (hunter/jumper),  
equestrian coach, assist with health care decisions and veterinarian  
procedures for performance horses, facility and stable maintenance  
and cleaning, website maintenance and design   
 
 
Volunteer Experience  
 Manning Equine Hospital:                    [2018 – present]  
  Vaccinations, administering medications, pharmaceutical preparation  
  (injections, medication), sheath cleaning, scrubbing and clipping  
  for procedures  
   
 Windsor-Essex Therapeutic Riding Association:                  [2015 – present]  
Strides for Stability Chair: Planning and execution of the Strides for  
Stability Fundraiser. Organizing and managing volunteers, obtaining  
sponsorship, organizing and obtaining prizes, planning and running of  

















































 Talbot Animal Hospital:                                                                    [2017 – Apr 2018]  
 Cleaning and facility maintenance, pharmaceutical preparations  
(injections, medication) assisting with simple procedures  
(IV line attachment and holding dog/cats/rabbits), active observer  
of procedures (appointments, surgery, x-ray), surgical pack preparation 
 
University of Windsor Equestrian Team:                         [2014 – 16]  
Treasurer: Organization and execution of the University of Windsor  
horse show, planning and execution of fundraising events, maintaining  
books and accounts for equestrian team 
 
 University of Windsor ‘Connecting4Success’:                         [2014 – 16]   
Mentor: Helping to guide first year students through the beginning of their  
undergraduate degree by helping them locate resources provided  
by the school, picking classes, encouraging professor-student rapport 
 
University of Windsor ‘Walk Safe’:                       [2014 – 16]  
Escorting students safely through campus after hours  
 
 Dr. Jack Speirs: 
Active observer in diagnostic imaging and interventional radiology,                  [2015] 
learning about various medical fields including cardiology, radiology,   
neurology, and anesthesiology, learning aseptic principles 
   
University of Windsor ‘Lead@UWindsor’                        [2014 – 15] 
 Volunteering at student run and organized events on campus 
 
 Bally Bright Dairy Farm:                                                             [summer 2013] 
  Dairy cow care (feed, handling, weaning), milking, cleaning, observation 
 
 Brack Animal Hospital:       [summer 2013] 
 Sweeping and cleaning, assisting with simple procedures  
(IV line attachment and holding dog/cats/rabbits), observation,  



















































Accomplishments, Awards and Scholarships  
Poster award – Robarts Research Retreat (2019) 
Poster award – Medical Residents Research Day (2018) 
3 Minute Thesis University of Western – Top 20 Finalist (2018) 
3 Minute Thesis Schulich School of Medicine and Dentistry – Finalist (2018) 
Western Graduate Research Scholarship (2017) 
‘Tutor of the Month’ Tutor Doctor (2017) 
Nominated for Outstanding Youth in Philanthropy Award (2016) 
University of Windsor Dean’s Honour Roll (2014 –16) 
Canadian Interprovincial Equestrian Championships – Individual bronze medalist, team gold medalist (2013) 
Ontario Outstanding Scholars Scholarship (Chemistry) (2012) 
University of Windsor Entrance Scholarship (Chemistry) (2012) 
 
 
  
